{"artifact":{"id":"experiment_proposal-4c8aa89b-1e99-41f2-9aa8-c960f8b9d16a","artifact_type":"experiment_proposal","entity_ids":"[\"Selective Acid Sphingomyelinase Modulation Therapy\"]","title":"Experiment Proposal (crux): Selective Acid Sphingomyelinase Modulation Therapy — Causal relationship between ASM elevation and disease initiation remains unprove","quality_score":0.5,"created_by":"crux_generator:skeptic","provenance_chain":"[]","content_hash":"4c71e513fff71efc7809a21eedcbcb2c1fb71077d252ca034c23ce6d07ffea5c","metadata":{"aims":["Determine whether ASM elevation is necessary for neurodegeneration onset by testing if selective ASM inhibition prevents disease initiation in validated models","Determine whether ASM elevation alone is sufficient to initiate neurodegeneration by testing if conditional ASM overexpression in healthy animals drives pathological outcomes","Establish temporal causality using inducible genetic models to determine whether ASM elevation precedes and predicts neurodegeneration onset"],"source":"debate_crux","hypotheses":["ASM elevation is necessary for neurodegeneration initiation: selective ASM inhibition will prevent disease phenotype emergence even in the presence of other pathological triggers","ASM elevation is sufficient to initiate neurodegeneration: ASM overexpression alone is sufficient to cause lysosomal dysfunction, neuroinflammation, and progressive neuronal loss in vivo","ASM elevation precedes neurodegeneration: temporally controlled ASM activation will demonstrate that pathological changes in lipid metabolism predict downstream neurodegenerative events"],"debate_type":"hypothesis_debate","est_cost_usd":520000.0,"persona_used":"Skeptic","crux_question":"Causal relationship between ASM elevation and disease initiation remains unproven","key_weaknesses":["Causal relationship between ASM elevation and disease initiation remains unproven","Existing pharmacological inhibitors lack selectivity (amitriptyline has >50 off-targets)","Correlative biomarker data could reflect downstream consequences of neurodegeneration","Limited human trial data for ASM-targeted approaches in neurodegeneration","Off-target effects of tricyclic inhibitors complicate safety and interpretation"],"_schema_version":1,"hypothesis_title":"Selective Acid Sphingomyelinase Modulation Therapy","protocol_summary":"Cohort 1 (Necessity Test): Cross Smpd1-floxed mice with 5xFAD mice; treat with either vehicle, amitriptyline (non-selective), or selective ASM inhibitor (20mg/kg/day i.p.) at pre-symptomatic age (8 weeks). Monitor: (a) ASM activity assay in brain homogenates (Amplex Red ceramide substrate), (b) longitudinal PET imaging of neuroinflammation [11C]-PK11195, (c) cognitive behavioral testing monthly, (d) survival endpoint histology for amyloid burden, neuronal count (NeuN), lysosomal markers (Lamp2). n=30 per group.\n\nCohort 2 (Sufficiency Test): Generate Smpd1-LSL;CamMKIIa-CreERT2 mice. At 8 weeks, induce ASM overexpression via tamoxifen (75mg/kg i.p. 5 consecutive days). Controls: Smpd1-LSL without Cre (overexpression absent), Cre-only (tamoxifen effects). Endpoints at 4, 12, 24 weeks post-induction: (a) SMPD1 activity assay, (b) ceramide quantitation by LC-MS/MS (brain regions), (c) EM for lysosomal morphology, (d)GFAP/Iba1 immunohistochemistry for gliosis, (e) caspase-3 activity assay, (f) cognitive testing.\n\nCohort 3 (Temporal Specificity): Smpd1-LSL;GFAP-CreERT2 mice crossed to Tau P301S. Perform tamoxifen at different time windows (pre vs. post tau pathology onset). Serial CSF sampling for neurofilament light chain (NfL) as biomarker. Endpoint analysis includes tau phosphorylation (AT8), neurofilament accumulation, behavioral decline.\n\nCohort 4 (Human iPSC Validation): Cerebral organoids from ASM-deficient (Niemann-Pick A) and NPD heterozygote lines, vs. isogenic CRISPR-corrected controls. Lentiviral SMPD1 overexpression to model elevated states. 90-day differentiation with longitudinal mass spectrometry for lipid species, confocal imaging for lysosomal pH (ratiometric dextran sensor), Seahorse XF for bioenergetics, RNA-seq at day 60 and 90.\n\nStatistical design: Two-way ANOVA with Bonferroni correction for behavioral data; Kaplan-Meier with log-rank for survival; Spearman correlation for biomarker temporal relationships. Pre-registered power analysis targets d=0.8 at α=0.05.","debate_session_id":"sess_hypdeb_h_de0d4364_20260427_071151","synthesis_summary":"The ASM modulation hypothesis presents a mechanistically plausible link between SMPD1 dysregulation and neurodegeneration through ceramide-mediated lysosomal destabilization, but faces significant challenges in establishing causality. The therapeutic rationale critically depends on developing selective ASM inhibitors, as the only clinically available option (amitriptyline) suffers from poor selectivity and off-target effects.","est_duration_weeks":78.0,"dataset_dependencies":["ASM selective inhibitor compound (e.g., sar入了 or custom-synthesized S1P analog with proven selectivity for SMPD1)","Smpd1-floxed mice for conditional knockout (available from Jackson Labs or collaborating colony)","Smpd1-LSL mice for Cre-dependent ASM overexpression (require generation from established Smpd1 targeting vector)","Cre-driver lines: CaMKIIa-CreERT2 (neuron-specific), CD68-Cre (microglia-specific), GFAP-CreERT2 (astrocyte-specific)","Neurodegeneration reporter strain: 5xFAD or Tau P301S mice on C57BL/6 background","iPSC lines fromASM deficiency (Niemann-Pick disease type A) and age-matched controls"],"falsification_criteria":"The causal hypothesis will be considered falsified if: (1) In Cohort 1, selective ASM inhibition fails to alter neurodegeneration trajectory despite confirmed enzyme inhibition (>70% reduction in activity); (2) In Cohort 2, ASM overexpression sufficient to cause >3-fold elevation in brain ceramide does NOT produce any measurable neurodegenerative phenotype at 24 weeks (defined as <10% change in neuronal count, no gliosis above baseline, no behavioral impairment); (3) ASM elevation in Cohort 2 occurs without preceding lysosomal dysfunction, suggesting ASM is downstream of lysosomal damage rather than upstream initiator; (4) In Cohort 4, human cerebral organoids with SMPD1 overexpression fail to reproduce neurodegenerative phenotypes observed in rodent models, suggesting species-specificity undermines therapeutic translation; (5) Amitriptyline and selective inhibitor show identical effect profiles, indicating ASM is not the relevant target.\n\nConversely, the null hypothesis (no causality) is falsified if: (a) ASM inhibition prevents disease in Cohort 1 AND ASM overexpression causes disease in Cohort 2, both with dose-response relationships; (b) temporal removal of ASM (genetic knockout after disease onset) halts progression in Cohort 3; (c) human iPSC models replicate the directionality observed in mouse models.","predicted_observations":"If ASM elevation is necessary: Cohort 1 will show selective ASM inhibitor significantly reduces neuroinflammation and cognitive decline in 5xFAD mice compared to vehicle, with amitriptyline showing intermediate effect due to off-target actions. Amyloid burden may be unchanged (confirming ASM acts downstream of amyloid), but lysosomal integrity and neuronal survival improve.\n\nIf ASM elevation is sufficient: Cohort 2 will show ASM overexpression alone causes progressive ceramide accumulation, lysosomal swelling, microglial activation, and cognitive decline in otherwise healthy mice by 24 weeks. Lysosomal pH will be elevated (deacidified). No amyloid or tau pathology will emerge, confirming ASM-mediated damage operates independently.\n\nIf temporal specificity exists: Cohort 3 will show ASM elevation during pre-symptomatic window accelerates neurodegeneration (NfL elevation precedes behavioral decline), while post-pathology ASM modulation is less effective, establishing a therapeutic window.\n\nIf ASM elevation is neither necessary nor sufficient: Cohort 1 will show no benefit from ASM inhibition; Cohort 2 will show no neurodegeneration despite ASM elevation; effect sizes will be nil or confounded by off-target actions."},"created_at":"2026-04-27T01:45:08.729046-07:00","updated_at":"2026-04-27T01:45:08.729046-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":null,"citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"b9f87a30-a0fb-4498-84d6-161dc7ab131d","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"crux_generator:skeptic"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[],"incoming_links":[{"source_artifact_id":"open_question-ccc7ad13-022a-4e84-b602-0e3bcef59981","link_type":"bears_on_question","strength":0.5,"evidence":"{\"confidence\": 0.5, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"source_artifact_id":"open_question-340bbca3-57bf-4fb8-b929-5f341a30d198","link_type":"bears_on_question","strength":0.4,"evidence":"{\"confidence\": 0.4, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"source_artifact_id":"open_question-3d912899-2516-49ac-bd36-b539cdca4b11","link_type":"bears_on_question","strength":0.55,"evidence":"{\"confidence\": 0.55, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"source_artifact_id":"open_question-55e21a3f-3ecf-4bab-9d7c-50334ae43b78","link_type":"bears_on_question","strength":0.45,"evidence":"{\"confidence\": 0.45, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"}],"current_artifact_id":"experiment_proposal-4c8aa89b-1e99-41f2-9aa8-c960f8b9d16a","is_canonical":true,"supersede_chain":["experiment_proposal-4c8aa89b-1e99-41f2-9aa8-c960f8b9d16a"]}